AR018633A1 - Derivados de benzo(b)tiepin-1,1-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo - Google Patents

Derivados de benzo(b)tiepin-1,1-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo

Info

Publication number
AR018633A1
AR018633A1 ARP990102715A ARP990102715A AR018633A1 AR 018633 A1 AR018633 A1 AR 018633A1 AR P990102715 A ARP990102715 A AR P990102715A AR P990102715 A ARP990102715 A AR P990102715A AR 018633 A1 AR018633 A1 AR 018633A1
Authority
AR
Argentina
Prior art keywords
radical
compounds
preparation
alkyl
tiepin
Prior art date
Application number
ARP990102715A
Other languages
English (en)
Original Assignee
Gompel Marie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gompel Marie filed Critical Gompel Marie
Publication of AR018633A1 publication Critical patent/AR018633A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Derivados de benzo(B)tiepin-1,1-dioxido, que comprenden compuestos de formula (I), en la cual significan: R1 es metilo, etilo, propilo, butilo;R2 es H, OH, NH2, NH-alquilo C1-6; R3 es un radical de sacárido, radical de disacárido, radical detrisacár ido, radical de tetrasacárido, pudiendoestar el radical de sacárido, el radical de disacárido, el radical de trisacárido o el radical de tetrasacárido mono- o plurisustituido por ungrupo protector de sacárido; R4 es metilo, etilo propilo,butilo; R5 es metilo, etilo propilo, butilo; Z es -(C=O)n-alquilo C0-16, -(C=O)n-alquilo C0-16-NH-,-(C=O)n-alquilo C0-16-O-, -(C=O)n-alquilo C0-16-(C=O)m, un enlace covalente; n es 0 o 1; m es 0 o 1; así como también con sus salesfarmacéuticamentecompatibles y sus derivados fisiologicamente funcionales, así como también procedimientos para su preparacion, medicamentos y empleo de dichos compuestospara la preparacion de medicamentos. Los compuestos son apropiados por ejemplocomo hipolipidémicos.
ARP990102715A 1998-06-10 1999-06-08 Derivados de benzo(b)tiepin-1,1-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo AR018633A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19825804A DE19825804C2 (de) 1998-06-10 1998-06-10 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
AR018633A1 true AR018633A1 (es) 2001-11-28

Family

ID=7870440

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990102716A AR018634A1 (es) 1998-06-10 1999-06-08 Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos.
ARP990102715A AR018633A1 (es) 1998-06-10 1999-06-08 Derivados de benzo(b)tiepin-1,1-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP990102716A AR018634A1 (es) 1998-06-10 1999-06-08 Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos.

Country Status (26)

Country Link
US (1) US6387944B1 (es)
EP (2) EP1086092B1 (es)
JP (2) JP4374426B2 (es)
KR (2) KR100681721B1 (es)
CN (2) CN1127497C (es)
AR (2) AR018634A1 (es)
AT (2) ATE227715T1 (es)
AU (2) AU753275B2 (es)
BR (2) BR9912188B1 (es)
CA (2) CA2334775C (es)
CZ (2) CZ297989B6 (es)
DE (3) DE19825804C2 (es)
DK (2) DK1086092T3 (es)
ES (2) ES2182535T3 (es)
HK (2) HK1036799A1 (es)
HU (2) HU229761B1 (es)
ID (2) ID28695A (es)
IL (1) IL140078A (es)
NO (1) NO327075B1 (es)
NZ (1) NZ508681A (es)
PL (2) PL196074B1 (es)
PT (2) PT1086092E (es)
RU (2) RU2215001C2 (es)
TR (2) TR200003634T2 (es)
WO (2) WO1999064410A1 (es)
ZA (2) ZA200007061B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
WO2002050027A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Deutschland Gmbh Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
HUP0401318A3 (en) * 2001-08-22 2008-03-28 Sanofi Aventis Deutschland Combined preparations containing 2,3,4,5-tetrahydro-benzo[b]thiepine-1,1-dioxide derivatives and other active substances, and the use thereof
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
PT1427423E (pt) 2001-09-08 2007-03-30 Astrazeneca Ab Derivados de benzotiazepina e benzotiadiazepina com actividade inibidora do transporte ileal de ácidos biliáres (ibat) para o tratamento de hiperlipidemia
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
US20040138145A1 (en) * 2002-12-12 2004-07-15 Aventis Pharma S.A. Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
DE102006053636B4 (de) * 2006-11-14 2008-09-18 Sanofi-Aventis Deutschland Gmbh Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung
DE102006053635B4 (de) * 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20100221513A1 (en) * 2008-09-05 2010-09-02 Wisconsin Alumni Research Foundation Self sintering transparent nanoporous thin-films for use in self-cleaning, anti-fogging, anti-corrosion, anti-erosion electronic and optical applications
US20110294767A1 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
WO2012064267A1 (en) 2010-11-08 2012-05-18 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
EP3777864A1 (en) 2010-11-08 2021-02-17 Albireo AB Ibat inhibitors for the treatment of liver diseases
SG10201903512SA (en) 2011-10-28 2019-05-30 Lumena Pharmaceuticals Inc Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
DK2771003T3 (en) * 2011-10-28 2017-07-17 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for the treatment of pediatric cholestatic liver disease
JP2016514684A (ja) 2013-03-15 2016-05-23 ルメナ ファーマシューティカルズ エルエルシー 原発性硬化性胆管炎および炎症性腸疾患の処置のための胆汁酸再循環阻害剤
CA2907214A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
EP3413878B1 (en) 2016-02-09 2021-04-14 Albireo AB Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
WO2019032027A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP3810581A1 (en) 2018-06-20 2021-04-28 Albireo AB Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
TWI835997B (zh) 2019-02-06 2024-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其用作膽酸調節劑之用途
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN113677398B (zh) 2019-02-06 2024-07-23 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
JP2022520121A (ja) 2019-02-12 2022-03-28 ミルム ファーマシューティカルズ インコーポレイテッド 胆汁うっ滞を治療する方法
JP2023504644A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
HUE065571T2 (hu) 2019-12-04 2024-06-28 Albireo Ab Benzotia(di)azepin vegyületek és alkalmazásuk epesav modulátorként
AR120683A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
AR120674A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiazepina y su uso como ácido biliar
PE20230234A1 (es) 2019-12-04 2023-02-07 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar
TW202134220A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CA3158276A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023504643A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
KR20230117393A (ko) 2020-12-04 2023-08-08 알비레오 에이비 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의용도
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
US20240067617A1 (en) 2022-07-05 2024-02-29 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US20240207286A1 (en) 2022-12-09 2024-06-27 Albireo Ab Asbt inhibitors in the treatment of renal diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3304093B2 (ja) * 1994-09-13 2002-07-22 モンサント カンパニー 回腸の胆汁酸輸送及びタウロコール酸塩吸収の阻害活性を有する新規ベンゾチエピン類
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
NZ331813A (en) * 1996-03-11 2001-03-30 G Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
EP1104416A2 (en) * 1998-08-20 2001-06-06 Takeda Chemical Industries, Ltd. Quaternary ammonium salts and their use as anti-hiv agents

Also Published As

Publication number Publication date
JP3374129B2 (ja) 2003-02-04
ES2182535T3 (es) 2003-03-01
IL140078A0 (en) 2002-02-10
PT1086092E (pt) 2003-03-31
CA2334773A1 (en) 1999-12-16
ATE227715T1 (de) 2002-11-15
WO1999064409A2 (de) 1999-12-16
HU228570B1 (en) 2013-04-29
DK1086092T3 (da) 2003-03-10
TR200003632T2 (tr) 2001-04-20
WO1999064410A1 (de) 1999-12-16
KR100562184B1 (ko) 2006-03-20
PL345901A1 (en) 2002-01-14
EP1086113B1 (de) 2004-02-11
DE19825804A1 (de) 1999-12-16
ID28695A (id) 2001-06-28
TR200003634T2 (tr) 2001-06-21
NO327075B1 (no) 2009-04-20
ID26876A (id) 2001-02-15
CA2334775C (en) 2009-10-13
PL196074B1 (pl) 2007-12-31
JP4374426B2 (ja) 2009-12-02
CZ297925B6 (cs) 2007-05-02
CN1152039C (zh) 2004-06-02
DE59908522D1 (de) 2004-03-18
RU2215001C2 (ru) 2003-10-27
CA2334773C (en) 2009-05-26
HK1036799A1 (en) 2002-01-18
BR9911123A (pt) 2006-01-03
NZ508681A (en) 2002-06-28
AU753275B2 (en) 2002-10-10
AR018634A1 (es) 2001-11-28
HU229761B1 (hu) 2014-06-30
HUP0102554A1 (hu) 2001-10-28
PL344827A1 (en) 2001-11-19
EP1086113A2 (de) 2001-03-28
ZA200007060B (en) 2001-07-18
BR9912188A (pt) 2001-04-10
RU2220141C2 (ru) 2003-12-27
PL196057B1 (pl) 2007-11-30
US6387944B1 (en) 2002-05-14
BR9912188B1 (pt) 2010-12-14
HUP0102256A3 (en) 2002-04-29
HK1039490A1 (en) 2002-04-26
KR20010052682A (ko) 2001-06-25
JP2002517490A (ja) 2002-06-18
WO1999064409A3 (de) 2000-03-02
CN1305469A (zh) 2001-07-25
DE59903411D1 (de) 2002-12-19
HUP0102554A3 (en) 2002-12-28
KR20010052701A (ko) 2001-06-25
CZ297989B6 (cs) 2007-05-16
ATE259372T1 (de) 2004-02-15
ZA200007061B (en) 2001-07-18
CA2334775A1 (en) 1999-12-16
CZ20004591A3 (cs) 2001-04-11
EP1086092B1 (de) 2002-11-13
JP2002517491A (ja) 2002-06-18
EP1086092A1 (de) 2001-03-28
CZ20004592A3 (cs) 2001-04-11
KR100681721B1 (ko) 2007-02-15
AU752633B2 (en) 2002-09-26
HUP0102256A1 (hu) 2001-12-28
CN1127497C (zh) 2003-11-12
AU4503199A (en) 1999-12-30
BR9911123B1 (pt) 2010-12-14
PT1086113E (pt) 2004-06-30
DK1086113T3 (da) 2004-05-24
ES2215387T3 (es) 2004-10-01
DE19825804C2 (de) 2000-08-24
IL140078A (en) 2004-08-31
NO20006251L (no) 2001-02-07
NO20006251D0 (no) 2000-12-08
CN1305487A (zh) 2001-07-25
AU4501999A (en) 1999-12-30

Similar Documents

Publication Publication Date Title
AR018633A1 (es) Derivados de benzo(b)tiepin-1,1-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo
ES2065904T3 (es) Hidroxietil-celulosa hidrofobamente modificada con carboximetilo (cmhmec) y uso de cmhmhec en composiciones de revestimiento protector.
RS49850B (sr) Derivati 1,4-benzotiazepin-1,1-dioksida supstituisani radikalima šećera, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena
PE20000048A1 (es) Prodrogas de inhibidores de aspartil proteasa
PL358428A1 (en) 9.alpha.-chloro-6.alpha.-fluoro-17.alpha.-hydroxy-16-methyl-17-beta-methoxycarbonyl-androst-1,4-dienes esterified in position 17.alpha. by a cyclic acyl group
AR045234A1 (es) Metodo para producir derivados del almidon de hidroxialquilo y composiciones farmaceuticas que los contienen.
AR071959A1 (es) Derivado de benceno o tiofeno y su uso como inhibidor de vap-1
BR9916772A (pt) Quinolinacarboxamidas como agentes antivirais
BR9707606B1 (pt) ácidos 8-ciano-1-ciclopropil-7-(2,8-diazabiciclo(4.3.0) nonan-8-il)-6-flúor-1,4-diidro-4-oxo-3-quinolinocarbo xìlicos, bem como medicamentos que os compreendem.
TR200100609T1 (tr) Sıvı çekici formunda dengelenmiş eczacılıkla ilgili bileşik
PE20020228A1 (es) Compuestos organicos como inhibidores de 3',5' guanosin monofosfato ciclico fosfodiesterasa
ES2176698T3 (es) Nuevos derivados de la eritromicina, su procedimiento de preparacion y su aplicacion como medicamentos.
BRPI0413353A (pt) composição farmacêutica contendo droga solúvel em água
NO20014529L (no) Tetrahydropyranderivater og deres anvendelse som terapautiske midler
ES2126966T3 (es) Proceso para la impregnacion hidrofuga de yeso.
AR018014A1 (es) Compuestos derivados de 3,6-hemicetales de la clase de los 9a-azalidos, un procedimiento para prepararlos y composiciones farmaceuticas que los comprenden.
AR023807A1 (es) Un agente para tratar el ojo seco y el uso de un compuesto macrolido para preparar composiciones farmaceuticas para el tratamiento del ojo seco
CO5070654A1 (es) Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden
ES2032335T3 (es) Nuevos derivados flavonoides 2-piperazinil-2-oxo-etilen sustituidos, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
ES2026555T3 (es) Derivados del piridoinol; su aplicacion a titulo de medicamentos y las composiciones que los contienen.
PE20010493A1 (es) Proceso para la preparacion de un analogo de carbonato de metilo del carbono 4, del paclitaxel
KR900014385A (ko) 제약학적 치료
AR035003A1 (es) Derivados de propanolamina relacionados con acidos biliares, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo para la preparacion de medicamentos
KR880013938A (ko) 활성 화합물들
AR030744A1 (es) Un polimero, o su sal, las composiciones farmaceuticas que lo contienen y el uso del mismo como medicamento o para la preparacion de medicamentos

Legal Events

Date Code Title Description
FG Grant, registration